Article Details

Sagard closes $725 million for biopharmaceutical royalty investment fund

Retrieved on: 2021-02-18 12:00:00

Tags for this article:

Click the tags to see associated articles and topics

Sagard closes $725 million for biopharmaceutical royalty investment fund. View article details on hiswai:

Excerpt

With a focus on investing in approved and commercialized biopharmaceutical products and diagnostics, SHRP also provides financing for medical ...

Article found on: betakit.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo